Challenged claims of Tecan Genomics Inc.'s patent that relates to the ability to discern artifacts arising through sequence duplications from nucleotide molecules are unpatentable as anticipated by and obvious over prior art, the Patent Trial and Appeal Board held, in an inter partes review by Qiagen Sciences LLC. The board determined that the challenged claims are anticipated by and obvious over various combinations of prior art, including prior art directed to methods of genotyping subjects and identifying and addressing different sources of ambiguity and error in genetic analyses, directed to addressing errors in next generation sequencing techniques, and directed to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.